Skip to main content
Home / The International Journal of Tuberculosis and Lung Disease, Volume 20, Number 7

The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

Publisher: International Union Against Tuberculosis and Lung Disease

More about this publication?
Volume 20, Number 7, 1 July 2016

EDITORIALS

Good news from the WHO
pp. 853-853(1)
Author: Davies, Peter D.

Favourites:
ADD

Calculating the economic benefits of what didn't happen
pp. 854-854(1)
Authors: Stout, Jason E.; Dicks, Kristen V.

Favourites:
ADD

When is a non-tuberculous mycobacterial infection a pulmonary disease?
pp. 855-856(2)
Authors: Griffith, D. E.; Lange, C.

Favourites:
ADD

PERSPECTIVES

Protein-calorie malnutrition, macronutrient supplements, and tuberculosis
pp. 857-863(7)
Authors: Koethe, J. R.; von Reyn, C. F.

Favourites:
ADD

ORIGINAL ARTICLES

Sputum smear microscopy result: a predictor for drug-resistant tuberculosis?
pp. 864-865(2)
Authors: Dean, A. S.; Zignol, M.; Lumb, R.; Lalor, M.; Skrahina, A.; Floyd, K.

Favourites:
ADD

Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap
pp. 866-869(4)
Authors: Stagg, H. R.; Hatherell, H-A.; Lipman, M. C.; Harris, R. J.; Abubakar, I.

Favourites:
ADD

Drug resistance and associated genetic mutations among patients with suspected MDR-TB in Uttar Pradesh, India
pp. 870-875(6)
Authors: Jain, A.; Singh, P. K.; Chooramani, G.; Dixit, P.; Malhotra, H. S.

Favourites:
ADD

Hypothyroidism during second-line treatment of multidrug-resistant tuberculosis: a prospective study
pp. 876-881(6)
Authors: Bares, R.; Khalid, N.; Daniel, H.; Dittmann, H.; Reimold, M.; Gallwitz, B.; Schmotzer, C.

Favourites:
ADD

Xpert® MTB/RIF detection of rifampin resistance and time to treatment initiation in Harare, Zimbabwe
pp. 882-889(8)
Authors: Metcalfe, J. Z.; Makumbirofa, S.; Makamure, B.; Sandy, C.; Bara, W.; Mason, P.; Hopewell, P. C.

Favourites:
ADD

Xpert® MTB/RIF for improved case detection of extra-pulmonary TB in a tertiary care setting in urban India
pp. 890-894(5)
Authors: Nataraj, G.; Kanade, S.; Mehta, P.

Favourites:
ADD

Mycobacterium tuberculosis bacteremia in adults and children: a systematic review and meta-analysis
pp. 895-902(8)
Authors: Pavlinac, P. B.; Lokken, E. M.; Walson, J. L.; Richardson, B. A.; Crump, J. A.; John-Stewart, G. C.

Favourites:
ADD

Diagnostic accuracy of a uniform research case definition for TBM in children: a prospective study
pp. 903-908(6)
Authors: Solomons, R. S.; Visser, D. H.; Marais, B. J.; Schoeman, J. F.; van Furth, A. M.

Favourites:
ADD

Outcome of tuberculous meningitis in children: the first comprehensive retrospective cohort study in Indonesia
pp. 909-914(6)
Authors: Nataprawira, H. M.; Ruslianti, V.; Solek, P.; Hawani, D.; Milanti, M.; Anggraeni, R.; Memed, F. S.; Kartika, A.

Favourites:
ADD

Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes
pp. 915-919(5)
Authors: McIlleron, H.; Hundt, H.; Smythe, W.; Bekker, A.; Winckler, J.; van der Laan, L.; Smith, P.; Zar, H. J.; Hesseling, A. C.; Maartens, G.; Wiesner, L.; van Rie, A.

Favourites:
ADD

Pilot study of the completeness of notification of adult tuberculosis in Athens, Greece
pp. 920-925(6)
Authors: Ibarz-Pavón, A. B.; Papaventsis, D.; Kalkouni, R.; Metaxas, G.; Spala, G.; Georgakopoulou, T.; Gerakis, T.; Pefanis, A.; Vogiatzakis, E.

Favourites:
ADD

Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades
pp. 926-933(8)
Authors: Castro, K. G.; Marks, S. M.; Chen, M. P.; Hill, A. N.; Becerra, J. E.; Miramontes, R.; Winston, C. A.; Navin, T. R.; Pratt, R. H.; Young, K. H.; LoBue, P. A.

Favourites:
ADD

Microbiological criteria in non-tuberculous mycobacteria pulmonary disease: a tool for diagnosis and epidemiology
pp. 934-940(7)
Authors: Jankovic, M.; Sabol, I.; Zmak, L.; Jankovic, V. Katalinic; Jakopovic, M.; Obrovac, M.; Ticac, B.; Bulat, L. Kardum; Grle, S. Popovic; Marekovic, I.; Samarzija, M.; van Ingen, J.

Favourites:
ADD

Evaluation of a TB infection control implementation initiative in out-patient HIV clinics in Zambia and Botswana
pp. 941-947(7)
Authors: Emerson, C.; Lipke, V.; Kapata, N.; Mwananyambe, N.; Mwinga, A.; Garekwe, M.; Lanje, S.; Moshe, Y.; Pals, S. L.; Nakashima, A. K.; Miller, B.

Favourites:
ADD

The impact of social conditions on patient adherence to pulmonary tuberculosis treatment
pp. 948-954(7)
Authors: Choi, H.; Chung, H.; Muntaner, C.; Lee, M.; Kim, Y.; Barry, C. E.; Cho, S-N.

Favourites:
ADD

Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand
pp. 955-960(6)
Authors: Maze, M. J.; Paynter, J.; Chiu, W.; Hu, R.; Nisbet, M.; Lewis, C.

Favourites:
ADD

Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California
pp. 961-966(6)
Authors: Shin, S. S.; Chang, A. H.; Ghosh, J. K. C.; Dubé, M. P.; Bolan, R.; Yang, O. O.; Kerndt, P. R.

Favourites:
ADD

Quantification of colony-forming units for M. tuberculosis complex using gyrB-based real-time PCR assay
pp. 967-972(6)
Authors: Yin, X-M.; Wu, L-J.; Zheng, L.; Mao, X-R.; Zhang, S-M.; Wang, Q.

Favourites:
ADD

Non-communicable diseases and risk of tuberculosis in Korea
pp. 973-977(5)
Authors: Oh, K. H.; Kim, H. J.; Kim, M. H.

Favourites:
ADD

Incidence and prevalence of idiopathic interstitial pneumonia and idiopathic pulmonary fibrosis in Korea
pp. 978-984(7)
Authors: Lee, H-E.; Myong, J-P.; Kim, H-R.; Rhee, C. K.; Yoon, H-K.; Koo, J-W.

Favourites:
ADD

CASE STUDY

Access to new drugs and the global drug-resistant TB crisis: a case series from KwaZulu-Natal, South Africa
pp. 985-987(3)
Authors: Master, I.; Furin, J.

Favourites:
ADD

CORRESPONDENCE

Targeting zero tuberculosis deaths among people living with HIV: a call for action
pp. 988-988(1)
Author: Deshmukh, Rajesh

Favourites:
ADD

Ensuring availability of the best tuberculosis treatment options in the Philippines
pp. 988-989(2)
Authors: Lessem, Erica; Frick, Mike

Favourites:
ADD

In reply: The language of tuberculosis
pp. 989-990(2)
Author: Castro, José Luis

Favourites:
ADD

Bacille Calmette-Guérin injection instead of purified protein derivative injection in an infliximab treated patient
pp. 990-991(2)
Authors: Aegerter, J P; Christin, L; Guyot, J; Zellweger, J-P

Favourites:
ADD

A multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs
pp. 991-992(2)
Authors: Gerona, Roy; Wen, Anita; Koss, Catherine; Bacchetti, Peter; Gandhi, Monica; Metcalfe, John

Favourites:
ADD

Screening for active tuberculosis in a diabetes mellitus clinic in Soweto, South Africa
pp. 992-993(2)
Authors: Majumder, Anwesha; Carroll, Bryn; Bhana, Sindeep; Tefu, Dorothy; Syeda, Sbaa; Martinson, Neil; Golub, Jonathan

Favourites:
ADD

ERRATA

Errata
pp. 994-994(1)

Favourites:
ADD

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content